Webpackaging logo

Aptar Pharma's Nanopharm wins Excellence in Pharma Award for SmartTrack

  • Aptar Pharma
Health, Pharmaceuticals, Shows, Associations, Media, Packaging Trade Shows, Events, CPhI, Packaging Awards

Aptar Pharma's Nanopharm has won an Excellence in Pharma Award at the 2019 CPhI Pharma Awards. Nanopharm, an Aptar Pharma company and part of their expanded services offering, won in the Contract Services and Outsourcing category for its recently launched SmartTrack™ process. Accepting the award were Dr. Jag Shur, CEO of Nanopharm, and Guillaume Brouet, Vice-President of Analytical, Regulatory and Scientific Affairs at Aptar Pharma.

The award was presented as part of the 16th annual CPhI Pharma Awards dinner, which took place Tuesday, November 5th at the Forum at Messe Frankfurt, Germany.

Established in 2004, the CPhI Pharma Awards are one of the most prestigious recognitions in the Pharmaceutical industry today, and celebrate the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. This year’s awards included 13 categories that span the entire industry’s supply chain.

A specialist in respiratory drug delivery services, Nanopharm is the world’s leading contract provider of orally inhaled and nasal drug product (OINDP) design and formulation development services to customers worldwide. Recognized for their advanced scientific understanding, Nanopharm offers an integrated solution approach via SmartTrack.

SmartTrack is a novel integrated solution providing an alternative bioequivalence (BE) clinical endpoint approach. SmartTrack can dramatically decrease program costs, mitigate risk and expedite development from concept to delivery, ensuring that every aspect of a drug product development’s critical path is optimized.

“This award marks a significant milestone for our SmartTrack platform, and signifies the R&D endeavor at Nanopharm to develop alternative bioequivalence strategies for OINDPs,” commented Jag Shur, PhD, Chief Executive Officer of Nanopharm. “I would like to thank our employees, clients and partners in this success.”

Aptar Pharma President Gael Touya, who was on hand to present the Excellence in Pharma Drug Delivery Device and Packaging Awards at this year’s event added, “We are delighted that Nanopharm’s SmartTrack™ was recognized by the industry for its innovative approach. This reinforces the Aptar Pharma Services mission to further help customers during their entire product lifecycle of the drug product and deliver them a complete solution.”

See also

Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products.

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

Aptar Pharma's electronic lockout device approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

  • Company News
  • English
  • Modified 06 Nov 2019
  • Hits 241